Fig. 5From: A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in TaiwanOverall stroke free rates for ACEi and ARB users after propensity score weighting. ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockersBack to article page